Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) EBITDA: 2021-2022

Historic EBITDA for Cardiol Therapeutics (CRDL) over the last 2 years, with Sep 2022 value amounting to -$6.1 million.

  • Cardiol Therapeutics' EBITDA rose 22.36% to -$6.1 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$7.2 million, marking a year-over-year change of. This contributed to the annual value of -$25.2 million for FY2021, which is 63.85% down from last year.
  • According to the latest figures from Q3 2022, Cardiol Therapeutics' EBITDA is -$6.1 million, which was down 20.09% from -$5.1 million recorded in Q2 2022.
  • In the past 5 years, Cardiol Therapeutics' EBITDA registered a high of $9.0 million during Q1 2022, and its lowest value of -$7.9 million during Q3 2021.
  • For the 2-year period, Cardiol Therapeutics' EBITDA averaged around -$3.9 million, with its median value being -$5.3 million (2021).
  • Data for Cardiol Therapeutics' EBITDA shows a peak YoY surged of 227.19% (in 2022) over the last 5 years.
  • Over the past 2 years, Cardiol Therapeutics' EBITDA (Quarterly) stood at -$5.0 million in 2021, then increased by 22.36% to -$6.1 million in 2022.
  • Its EBITDA was -$6.1 million in Q3 2022, compared to -$5.1 million in Q2 2022 and $9.0 million in Q1 2022.